Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...

To suggest Sarepta Therapeutics may not survive its gene therapy crisis is a sobering claim to make, STAT's Adam Feuerstein ...

For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...

In this week’s edition of InnovationRx, we look at Moderna’s use of quantum computers, a new top drug regulator at the FDA, ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of ...

Sarepta Therapeutics shares were lower in premarket trading on Tuesday, as the drugmaker relented to a Food and Drug Administration request to halt shipments of a gene therapy. Sarepta shares (SRPT) ...

Asian markets are mixed after U.S. stock indexes hit new records on Monday. Oil prices fell and U.S. futures were little ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose 0.1% and squeaked past its prior ...